UNSPSC 51171845: Nantradol

This classification denotes an analgesic agent with the molecular formula C27H35NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9KB5WI7MQ6, chemically known as 1,9-phenanthridinediol, 5,6,6a,7,8,9,10, 10a-octahydro-6-methyl-3-(1-methyl-4-phenylbutoxy)-, 1-acetate, hydrochloride, (6a,6a.alpha.,9.alpha.,10a.beta.)- but generally known as nantradol, which bears US NIH Compound Identifier 107822. European Medicines Agency schedules Nantradol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09151MIG.

UNSPSC 51171845 Nantradol is a Commodity code that covers pharmaceutical products, though recent state and local solicitations under this code show minimal activity directly aligned with nantradol itself. The three most recent opportunities tagged to this code span offender drug testing services, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals—a scattered mix that reflects broader state and local procurement of pharmaceutical products and testing services rather than nantradol specifically. State and local issuing bodies soliciting under this code include county community supervision departments, state health and human services commissions, and multistate cooperative purchasing alliances. Collin County Community Supervision and Corrections Department in Texas is actively procuring offender specimen collection and drug testing services, while the Texas Health and Human Services Commission is gathering market intelligence on direct-to-manufacturer pharmacy programs, and the Minnesota Multistate Cooperative Purchasing Alliance (administered by the Minnesota Department of Administration) is establishing contracts for generic pharmaceuticals and OTC products with participating states including Oregon.

Recent opportunities are concentrated in Texas and Minnesota, with geographic reach extending to Oregon through cooperative purchasing. The Collin County RFP 2026-327 for offender specimen collection and drug testing services carries an estimated contract value of $600,000 and closes July 23, 2026, covering staffing of two sites in Plano and McKinney with approximately 25,031 annual tests and lab certifications required from SAMHSA, TX DPS, or CAP. The Minnesota Multistate Cooperative Purchasing Alliance RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products closed March 26, 2026, requiring vendors to supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification. The Texas Health and Human Services Commission RFI HHS0017013 on direct-to-manufacturer prescriptions closed April 3, 2026 as an exploratory market-research phase. The code shows limited recent activity specifically tied to nantradol procurement; business development professionals should verify whether opportunities tagged to this code align with actual firm capabilities before pursuing.